Global Eyedrops for Cataract Market Size By Type (Phacolin, Catalin), By Application (Adult, Children), By Region, And Segment Forecasts, 2023 to 2032

The Global Eyedrops for Cataract Market was valued at USD 820 million in 2023 and is projected to surpass USD 1.35 billion by 2031, growing at a CAGR of 6.5% during the forecast period of 2023–2031. This growth is driven by the increasing global prevalence of cataracts, especially among the aging population, combined with rising demand for non-invasive and cost-effective treatment alternatives to cataract surgery. Ongoing research in ophthalmology and drug development is enhancing the efficacy of eyedrop-based treatments, contributing to the market's expansion.

Drivers:

1. Rising Geriatric Population:

The aging demographic is a significant driver of cataract prevalence worldwide. As cataracts remain the leading cause of blindness globally, the demand for eyedrops as preventive and therapeutic options continues to rise.

2. Growing Preference for Non-Invasive Treatments:

Patients and healthcare providers are increasingly favoring non-surgical treatment options. Eyedrops for cataract, particularly those in clinical trials claiming to reverse lens opacity, are gaining momentum.

3. Increasing Investments in Ophthalmic Research:

Biotech and pharmaceutical companies are investing heavily in R&D for novel ophthalmic solutions, including lanosterol-based and steroid-free formulations, supporting market growth.

Restraints:

1. Limited Clinical Validation:

While several eyedrop formulations are under development, many lack robust clinical validation. Regulatory challenges and the absence of FDA-approved non-surgical cataract eyedrops constrain wider adoption.

2. Availability of Surgical Alternatives:

Cataract surgery remains a highly successful and commonly performed procedure. Its availability and high success rate may limit the widespread adoption of eyedrop-based alternatives.

Opportunity:

1. Untapped Emerging Markets:

In developing nations, access to surgical facilities remains limited. Affordable and accessible cataract eyedrops present an immense opportunity to address the unmet medical needs in these regions.

2. Breakthrough Innovations in Nanomedicine and Drug Delivery:

Advanced drug delivery systems and nanotechnology-based eyedrop formulations are expected to improve drug absorption and efficacy, opening up new revenue streams for manufacturers.

Market by System Type Insights:

Based on system type, the Steroid-Free Eyedrops segment accounted for the largest market share in 2023. These formulations are favored for long-term use due to minimal side effects. However, Lanosterol-Based Eyedrops are anticipated to witness the highest growth rate through 2031, driven by their potential to dissolve cataract-forming protein aggregates non-surgically—a promising innovation still in clinical stages.

Market by End-Use Insights:

The Hospital Pharmacies segment emerged as the largest revenue contributor in 2023. These settings are preferred for the prescription and initial dispensing of specialized ophthalmic treatments. Meanwhile, Online Pharmacies are expected to register the fastest growth, bolstered by the digitalization of healthcare and the convenience of home delivery for repeat prescriptions.

Market by Regional Insights:

North America led the global eyedrops for cataract market in 2023 due to the region's advanced healthcare infrastructure, high awareness, and strong presence of pharmaceutical innovators. However, Asia-Pacific is projected to be the fastest-growing region, propelled by an aging population, rising cataract prevalence, and expanding access to affordable eye care solutions in countries like India and China.

Competitive Scenario:

Key players in the Global Eyedrops for Cataract Market include:

Novartis AG

Johnson & Johnson Vision

Otsuka Pharmaceutical Co., Ltd.

NICOX S.A.

ViewPoint Therapeutics

Senju Pharmaceutical Co., Ltd.

Allegro Ophthalmics

Encore Vision Inc.

Lanomax

Sun Pharma

These companies are actively investing in clinical trials, expanding distribution networks, and forming strategic alliances to commercialize innovative eyedrop formulations for cataract management.

Scope of Work – Global Eyedrops for Cataract Market

Report Metric Details

Market Size (2023) USD 820 million

Projected Market Size (2031) USD 1.35 billion

CAGR (2023–2031) 6.5%

Market Segments By System Type (Steroid-Free, Lanosterol-Based), By End-Use (Hospitals, Clinics, Online Pharmacies), By Region

Growth Drivers Rising geriatric population, demand for non-invasive treatments, R&D investment in ophthalmology

Opportunities Emerging markets, nanomedicine innovations

Key Market Developments:

2023: ViewPoint Therapeutics advanced its VP-001 lanosterol-based eyedrop into Phase II clinical trials, showing promising safety and efficacy in early-stage cataract patients.

2024: Novartis AG partnered with a biotech start-up to co-develop a new class of anti-cataract eyedrops based on protein refolding technology.

2025: Johnson & Johnson Vision announced the global launch of an AI-powered diagnostic platform integrated with their ophthalmic product lines, enhancing treatment personalization.

FAQs:

1) What is the current market size of the Global Eyedrops for Cataract Market?

The market was valued at USD 820 million in 2023.

2) What is the major growth driver of the Global Eyedrops for Cataract Market?

The increasing geriatric population and growing preference for non-surgical treatments are key drivers.

3) Which is the largest region during the forecast period in the Global Eyedrops for Cataract Market?

North America is the leading region, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in Global Eyedrops for Cataract Market?

Steroid-Free Eyedrops dominated the market in 2023.

5) Who are the key market players in the Global Eyedrops for Cataract Market?

Key players include Novartis AG, Johnson & Johnson Vision, ViewPoint Therapeutics, and Otsuka Pharmaceutical Co., Ltd.